RAC Race Oncology Limited
—Mkt Cap: —P/E: —1d ago
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leuke…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value189.04M USD
Revenue (TTM)1.94M USD
Gross Profit1.19M USD
Net Income (TTM)-7.66M USD
Revenue/Share0.02 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000RAC3
Valuation
P/E (Trailing)—
P/E (Forward)-15.24
PEG—
EV/EBITDA-27.02
EV/Revenue97.31
P/S109.51
P/B8.44
EPS (TTM)-0.06
EPS (Forward)-0.10
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin61.22%
Oper. Margin-370.08%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-30.42%
ROA-29.11%
Growth
Revenue Growth-12.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.70M USD
CapEx (TTM)2.54K USD
FCF Margin-139.29%
FCF Yield—
Net Debt-23.70M USD
Net Debt/EBITDA3.39
Balance Sheet
Debt/Equity—
Current Ratio21.43
Quick Ratio21.28
Book Value/Sh0.19 AUD
Cash/Share0.17 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.196.07M
Float136.32M
Insiders27.08%
Institutions0.10%
Technical
SMA 502.006 AUD
SMA 2002.351 AUD
Beta0.91
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)79.34K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—